Related Experiment Videos
Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides
1Institute of Pathology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany.
Abstract:
More than one third of human soft tissue sarcoma (STS) have elevated levels of the MDM2 oncoprotein, resulting either from gene amplification or alternate mechanisms. MDM2 functions as a negative feedback regulator of the tumor suppressor p53. The aim of the present study was to investigate whether mdm2-antisense oligodeoxyribonucleotides (AS-ODNs) can influence the growth characteristics of two MDM2-overexpressing STS cell lines (US8-93, LMS6-93) where both have heterozygous p53 non-missense mutations. Cells were treated with lipofectamine-complexed mdm2 AS-ODNs complementary to a sequence of the mdm2 cDNA initiation site in comparison to sense control ODNs. After seeding and cultivation of a defined cell number the clonogenic survival was performed. The treatment of US8-93 cells with AS-ODNs, but not with sense ODNs, decreased the number of colonies up to > 80%. Western blot analysis demonstrated a significant decreasing of MDM2 protein level in AS-ODN transfected cells indicating an AS-specific inhibition of mdm2 transcription in US8-93 cells. Additionally, an increase of the G2/M population was found. In contrast, in the LMS6-93 cells treated with AS-ODNs only a decrease in clonogenic survival up to 26%, no change in MDM2 protein level and no cell cycle alterations were seen. All these factors taken together into consideration can be suggest that lipid-mediated mdm2 AS-ODNs could be as an effective therapeutic strategy for STS with an abnormal mdm2 overexpression.
Insights
MDM2-antisense oligodeoxyribonucleotides (AS-ODNs) show promise in treating soft tissue sarcoma (STS) by reducing MDM2 oncoprotein levels and inhibiting tumor cell growth, particularly in cell lines with high MDM2 expression.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Over one-third of soft tissue sarcomas (STS) exhibit elevated MDM2 oncoprotein levels, which negatively regulate the tumor suppressor p53.
- MDM2 overexpression can result from gene amplification or other mechanisms, contributing to cancer progression.
Purpose of the Study:
- To investigate the efficacy of mdm2-antisense oligodeoxyribonucleotides (AS-ODNs) in modulating the growth characteristics of MDM2-overexpressing STS cell lines.
- To assess the impact of AS-ODNs on MDM2 protein levels, cell survival, and cell cycle progression in specific STS models.
Main Methods:
- Two STS cell lines (US8-93, LMS6-93) with heterozygous p53 non-missense mutations and MDM2 overexpression were treated with lipofectamine-complexed mdm2 AS-ODNs.
- Clonogenic survival assays and Western blot analysis were performed to evaluate the effects of AS-ODNs compared to sense control ODNs.
- Cell cycle analysis was conducted to determine alterations in cell population distribution.
Main Results:
- AS-ODN treatment significantly reduced colony formation by over 80% in US8-93 cells, accompanied by decreased MDM2 protein levels and an increased G2/M cell cycle population.
- In contrast, LMS6-93 cells showed only a 26% decrease in clonogenic survival, with no significant changes in MDM2 protein levels or cell cycle distribution.
- These findings indicate an AS-ODN-specific inhibition of mdm2 transcription in the US8-93 cell line.
Conclusions:
- Lipid-mediated mdm2 AS-ODNs demonstrate potential as an effective therapeutic strategy for STS characterized by abnormal MDM2 overexpression.
- The differential response between cell lines suggests that the efficacy of AS-ODNs may depend on specific genetic backgrounds and MDM2 regulatory mechanisms.
- Further investigation is warranted to optimize AS-ODN therapy for soft tissue sarcomas.